首页 | 本学科首页   官方微博 | 高级检索  
检索        

阴沟肠杆菌的产酶性及抗菌药物的体外联合抗菌活性研究
引用本文:扈会整,刘婧,吴斌艳,刘汉芳,任超杰,任伟娟,林赞.阴沟肠杆菌的产酶性及抗菌药物的体外联合抗菌活性研究[J].陕西医学检验,2014(3):118-120.
作者姓名:扈会整  刘婧  吴斌艳  刘汉芳  任超杰  任伟娟  林赞
作者单位:陕西省核工业215医院,陕西咸阳712000
摘    要:目的 探讨咸阳地区阴沟肠杆菌的产酶现状及其抗菌药物的应用.方法 收集2012年6月-2013年5月临床分离无重复的100株阴沟肠杆菌,采用KB琼脂扩散法检测超广谱β内酰胺酶(ESBLs)和通过改良三维试验检测AmpC,碳青霉烯酶的检测采用亚胺培南+ EDTA法,MIC检测采用微量倍比稀释法,按CLSI法规进行.结果 在100株阴沟肠杆菌中,产ESBLs酶的为49%,产AmpC酶的为29%,碳青霉烯酶的为0%,同时产ESBLs和AmpC酶为29%.药敏结果是哌拉西林/他唑巴坦、头孢哌酮/舒巴坦、美洛培南、头孢吡肟、环丙沙星、阿米卡星和头孢他啶的抑菌率分别为64.7%,58.8%,100%,70.6%,70.6%,64.7%,41.1%.联合药物头孢吡肟、哌拉西林/他唑巴坦、美洛培南、头孢哌酮/舒巴坦与阿米卡星对阴沟肠杆菌的协同及相加作用分别为(17.64-41.18)%,(11.76-47.06)%,(5.88-52.94)%和(0-58.83)%.联合药物头孢吡肟、哌拉西林/他唑巴坦、美洛培南、头孢哌酮/舒巴坦与环丙沙星对阴沟肠杆菌协同及相加作用分别为(11.76-23.54)%,(5.88-11.77)%,(11.77-47.06)%和(5.88-17.65)%.结论 产酶的阴沟肠杆菌在该地区处于一个相对较高的水平,因此临床医师应根据药敏结果选用抗菌药物.

关 键 词:阴沟肠杆菌  ESBLs酶  AmpC酶  碳青霉烯酶  联合用药

Study on Capability of Producing Enzyme of Enterobacter Cloace and Antibacterial Activity of Combined Antibacterials in Vitro
Authors:HU Hui-zheng  LIU Jing  WU Bin-yan  LIU Han-fang  REN Chao-jie  REN Wei-juan  LIN Zan
Institution:1.Shaanxi Nuclear Industry 215 Hospital, Shaanxi Xianyang 712000, China)
Abstract:Objective To study the Xianyang region's Enterobacter cloace enzyme production and application of antimicrobial drugs.Methods Collected in June 2012 to May 2013 clinical separation,no repeat 100 bead sewer Enterobactercloacae.The K B super broad spectrum extended spectrum β lactamases (ESBLs) and modified three dimensional of cefiriaxone test were used to detect AmpC,carbapenems enzyme medthod of detection with imipenem and EDTA.Results Isolate 100 strains from clinical specjmens of infection of sewer Enterobacter cloacae,including producing ESBLS enzyme was 49 %.Production of AmpC enzyme was 29 %.Carbapenems enzyme was 0 %,at the same time,producing ESBLS AmpC enzyme was 29 %,and piperacillin/tazobactam,cefoperazone/sulbactam,meropenem,cefepime ciprofloxacin,amilacin and ceftazidime bacteriostatic rates totally were 64.7%,58.8%,100%,70.6%,70.6%,64.7% and 41.1 %,respectively.Combination of drugs cefepime,piperacillion/tazobactam,meropenem,cefoperazone/sulbactam and amikacin to sewer synergy and the processing effect of en terobacter cloacae were 17.64%-41.18%,11.76%-47.06%,5.88%-52.94% and 0-58.83%,respectively.Combina tion of drugs cefepime,piperacillion/tazobactam,meropenem,cefperazone/sulbactam and ciprofloxacin on sewer synergy and the processing effect of enterobacter cloacae were 11.76%-23.54%,5.88%-11.77%,11.77%-47.06% and 5.88%- 17.65%,respectively.Conclusion Enzyme production of sewer enterobacter cloacae in the region was in a relatively high level,so clinicians should select different antimicrobial agents according to the results of drug susceptibility.
Keywords:enterobacter cloacae  extended spectrum β lactamases(ESBLs)  ampc enzymes  carbapenems enzyme  combination
本文献已被 维普 等数据库收录!
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号